Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

C. Kalil, André; F. Patterson, Thomas; K. Mehta, Aneesh; M Tomashek, Kay; R. Wolfe, Cameron; Ghazaryan, Varduhi; C. Marconi, Vincent; M. Ruiz‐Palacios, Guillermo; Hsieh, Lanny; Kline, Susan; F. Tapson, Victor; M. Iovine, Nicole; K. Jain, Mamta; A Sweeney, Daniel; M. El Sahly, Hana; R Branche, Angela; Regalado Pineda, Justino; Chien Lye, David; Sandkovsky, Uriel; F. Luetkemeyer, Anne; H. Cohen, Stuart; W. Finberg, Robert; Jackson, Patrick; Taiwo, Babafemi; I. Paules, Catharine; Arguinchona, Henry; Erdmann, Nathaniel; Ahuja, Neera; G. Frank, Maria; Oh, Myoung‐don; Suk Kim, Eu; Yen Tan, Seow; A. Mularski, Richard; Nielsen, Henrik; O. Ponce, Philip; S. Taylor, Barbara; Larson, LuAnn; Rouphael, Nadine; Saklawi, Youssef; D Cantos, Valeria; R. Ko, Emily; J. Engemann, John; Amin, Alpesh; Watanabe, Miki; Billings, Joanne; Elie, Marie‐Carmelle; T. Davey, Richard; Burgess, Timothy; Ferreira, Jennifer; Green, Michelle; Makowski, Mat; Cardoso, Anabela; de Bono, Stephanie; Bonnett, Tyler; A. Proschan, Michael; A. Deye, Gregory; Dempsey, Walla; Nayak, Seema; E. Dodd, Lori; H. Beigel, John

doi:10.1056/nejmoa2031994

Public

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Published in New England Journal of Medicine • Dec 11, 2020

Authors:

André C. Kalil

Thomas F. Patterson

Aneesh K. Mehta

Abstract

BACKGROUND: Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS: We conducted a double-blind, randomized, placebo-controlled trial evaluating b...

Subject

Coronavirus disease 2019 (COVID-19)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

2019-20 coronavirus outbreak

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!